Company: NCNA
Filing Date: 2025-03-20
Form Type: 20-F
Source: 0000950170-25-042709
Chunk: 4

Company: NuCana plc
Filing Date: 2025-03-20
Form: 20-F
Item: Item 3
Chunk 4
---
 combination with docetaxel for patients with lung cancer. It may be several years, if ever, before we have a product candidate ready for commercialization. To date, we have financed our operations primarily through public and private placements of our equity securities. We expect to continue to incur significant expenses and operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that our expenses will increase substantially if and as we:
 •continue development of our ProTides, including completing ongoing clinical trials and initiating additional clinical trials of NUC-7738 and NUC-3373;
 •complete preclinical studies and potentially initiate clinical trials of any preclinical-stage product candidates;
 •identify and develop new product candidates;
 •establish a robust supply chain for the manufacture of our product candidates in accordance with current good manufacturing practice, or cGMP;
 •seek marketing approvals for our product candidates that successfully complete pivotal clinical trials;
 •establish a sales, marketing and distribution infrastructure to commercialize any products for which we obtain marketing approval;
 •pursue market acceptance of our product candidates in the medical community and with third-party payors;
 •maintain, expand and protect our intellectual property portfolio;
 •expand our headcount by recruiting personnel to drive our clinical development programs and effectively manage out-sourced development activities;
 •enter into collaboration arrangements, if any, for the development of our product candidates or in-license other products and technologies;
 •achieve milestones which will trigger payments under our license agreements; and
 •add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts.
 In addition, protecting our intellectual property may result in litigation aimed at enforcing or defending our patents. Intellectual property litigation is expensive and, in the event that we lose any such litigation, we may be subject to additional significant legal expense, including the potential requirement to pay the legal expenses of opposing parties.
 Because of the numerous risks and uncertainties associated with developing new pharmaceutical drugs, we are unable to predict the extent of any future losses or when we will become profitable, if at all. In addition, our expenses could increase beyond expectations if we are required by the Food and Drug Administration, or FDA, the European Medicines Agency, or EMA, or other foreign regulatory agencies, to perform studies and clinical trials in addition to those that we currently anticipate, or if there are any delays in the completion of planned clinical trials or the development of any of our ProTides.
 To become and remain